Gonadorelin FAQ: common questions answered
A short-acting fertility hormone used in tests and specialist pump therapy.
Also called: GnRH, LHRH, gonadorelin acetate, gonadorelin hydrochloride, Factrel, Lutrepulse.
Reproductive axis peptides · Gonadotropin-releasing hormone receptor agonist · Evidence: Approved drug.
- Is Gonadorelin FDA-approved? Yes: Factrel, human product; discontinued (historical diagnostic gonadorelin hydrochloride product.); Lutrepulse Kit; discontinued (historical gonadorelin acetate for GnRH-deficient ovulation induction.). All human products under these NDAs are discontinued. No approved TRT-add-on indication; veterinary Factrel is a different product.
- How do people take it? Under the skin, every 3.5 days. Source: reported by users, not an established dose.
- What's the difference between Gonadorelin and Kisspeptin-10? Gonadorelin: a short-acting fertility hormone used in tests and specialist pump therapy. Kisspeptin-10: a short-acting experimental peptide that triggers reproductive hormone release. Why people pair them: reported as a second reproductive-axis stimulant. No human combination trial was found.
- Can I take it with Kisspeptin-10? Reported as a second reproductive-axis stimulant. No human combination trial was found. Hormone and fertility effects of the combination are unknown. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). The S2.2.1 restriction applies to male athletes. The ingredient, formulation and athlete-specific therapeutic use exemption must be checked with the antidoping authority.
- How long does a mixed vial last? Refrigerate after mixing and use within 24 hours; discard unused solution.
Related to Gonadorelin
- Kisspeptin-10: A short-acting experimental peptide that triggers reproductive hormone release.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
Sources
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- FDA warning letter 729447: unapproved gonadorelin (2026-06-17), FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- FDA CDER alert: compounded-drug recall for lack of sterility assurance (2022-04-26), FDA · 2022
- Gonadorelin 100 micrograms powder for solution for injection, Esteve Pharmaceuticals · 2022
- Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment., Boehm U et al. · Nature reviews. Endocrinology · 2015
- Base de Données Publique des Médicaments, ANSM
- Drugs@FDA: FDA-Approved Drugs, FDA
- Drugs@FDA: FDA-Approved Drugs, FDA
- FD&C Act Provisions that Apply to Human Drug Compounding, FDA · FDA
- PREGNYL- choriogonadotropin alfa kit, Organon
- Product information, Health Canada
- Successful ovulation and pregnancy with pulsatile GnRH pump therapy in a polycystic ovary syndrome (PCOS) patient: a case report., Wang S et al. · Frontiers in endocrinology · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.